The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. To understand the implications of this growth, the Trinity Life Sciences Evidence Strategy team sought to gain a multi-disciplinary view on where and how HEOR experts see the field evolving and to better understand how HEOR capabilities can be…
Read Now
The Example of ASH 2021
Medical conferences are designed to bring bright minds together and pique interest and curiosity. The American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Society for Medical Oncology (ESMO), Gene Therapy for Rare Disorders, and other medical conferences play an important role in disseminating clinical and scientific information. Attendees range from physicians to investors, and the conferences provide a forum for peer-to-peer interactions, exposure to current research, innovative trends and an environment…
Read Now
Providing optimal care to all patients is an imperative that unites the various, interconnected parts of the medical field, from primary care to the pharmaceutical industry to the work of large academic medical centers. Over the past 30 years, there have been exceptional advances in care, treatment, diagnostics, and early identification of disease. Unfortunately, even with these many technological advances, addressing the importance of diversity has been lagging. Since the advent of clinical trials, recruitment has been largely centered on…
Read Now
Over the past few years, there has been a spotlight on gender representation in leadership in a wide range of industries. Women are underrepresented in healthcare and biotech companies, despite evidence showing that companies that don’t have equitable representation perform worse compared to those that do.
While this is recognized, there is a lack of understanding about the scope of the problem within life sciences consulting. In general, there is a lack of transparency on these issues, with a resulting…
Read Now
Patient Finding is an innovative tool to improve customer targeting that can be implemented fairly quickly, without a lot of organizational disruption, retraining, or complex data integration. It is a worthwhile addition to your portfolio of targeting methods.
For appropriate brands, Patient Finding can provide a significant competitive advantage. As it becomes more widely used by the pharma industry, late adopters may find themselves at a competitive disadvantage.
Complete the form below to access “Why you should consider Patient Finding…
Read Now
The Example of ASCO 2021
While people were expecting to return to in-person conferences soon, the emergence of the Delta variant and the possibility of future unknown variants, combined with uneven vaccination rates, has created significant uncertainty about how soon that can happen. Trinity Life Sciences wanted to understand what perceptions medical conference attendees had of the new virtual conference world, what advantages and disadvantages they saw in it, and how manufacturers performed at engaging their audiences. We performed a…
Read Now
Despite the challenges the COVID-19 pandemic created, 2020 was an exceptional year for the biopharma industry. The race to develop effective treatments and vaccines for COVID elevated the public’s perception of biotechnology, and, for many, the industry provided a source of hope during the pandemic. As early-stage venture capitalist Bruce Booth observed in his review of 2020, investors’ enthusiasm sent biotech indexes to all-time highs, boosted the performance of IPOs and accelerated venture capital funding. The NASDAQ Biotech Index finished…
Read Now
In this article, we aim to explain how monoclonal antibodies can help in the fight against the COVID-19 pandemic. While there are still unknowns about these drugs – such as their real-life efficacy and long-term effects, amongst others –antibodies nonetheless have the potential to effectively target several stages of the disease with evident benefits at a patient level (by alleviating symptoms and preventing progression to severe disease) and at a systemic level (by reducing the strain on the overburdened health…
Read Now
What is and isn’t working for drug launches amid COVID-19? Six months after COVID-19 lock-downs began, Trinity has uncovered some surprising (and some concerning) answers to key questions everyone is asking.
In this paper, we examine the trajectory of new molecular entities (NMEs) approved in late 2019 and early 2020 to understand how to drive a successful drug launch (and avoid the pitfalls) in the age of COVID-19.…
Read Now
2018 and 2019 were banner years for approvals with over 50 drugs approved by the FDA and the EMA each year. 2020 looks no different. As you prepare for your unique launch in an ever-changing landscape, we understand the challenges you may face: limited resources, lack of prioritization, misalignment, diversity of markets. Based on Trinity’s experience supporting dozens of launches in 2019 alone and through a landmark research study with 30 Chief Commercial Officers (CCOs) who had recently launched a…
Read Now
